“Cyber Device” Is in the Message. Which Section 524B Evidence Is Still Missing?

Signals to watch

• A named medical device and software version are tied to a 510(k), De Novo, PMA or other covered premarket submission decision
• The team can state why the product does or does not meet every part of the statutory cyber-device definition
• Section 524B evidence and wider FDA premarket cybersecurity documentation can be tied to the same submitted version and accountable owners

Calling a product a “cyber device” does not show that its FDA premarket cybersecurity evidence is ready. First test the statutory definition against one named device and version. Then connect that same version to the section 524B postmarket vulnerability plan, secure-development and patch processes, software bill of materials, any other required information, and the wider cybersecurity documentation FDA expects for review. A missing connection identifies the work; a list of document names does not.

This is the evidence problem facing a medical-device cybersecurity consultancy business-development lead following authorised Telegram groups used by device manufacturers, digital-health regulatory teams, product-security specialists and premarket-submission professionals. The useful Signal is a named device approaching a 510(k), De Novo, premarket approval application (PMA) or another covered submission while different owners are asking who has the threat model, software bill of materials (SBOM), coordinated vulnerability-disclosure procedure or patch plan. Seeing it a day late can mean the submission team has already frozen its evidence index or assigned the repair elsewhere. It does not prove scope, authority, budget or FDA readiness.

Question 1: Does this exact product meet the cyber-device definition?

Not every device containing software is automatically a cyber device. Under 21 U.S.C. § 360n-2, the product must meet three parts: it includes software validated, installed or authorised by the sponsor as a device or in a device; it can connect to the internet; and it contains sponsor-validated, installed or authorised technological characteristics that could be vulnerable to cybersecurity threats.

Apply those words to the configuration in the application. Record the model, hardware revision, software release, connectivity path, related systems and the sponsor’s basis for each part of the definition. “Cloud enabled” is not enough if nobody can say what communicates, through which product characteristic or for which submitted version. Likewise, a disconnected operating mode does not by itself answer whether the device has the ability to connect.

If the group discussion has only a family name and “contains software”, the first engagement is an applicability and product-boundary review. Do not sell evidence remediation before the assessment object exists.

Question 2: Which section 524B submission element is absent?

Section 524B is not one cybersecurity report. For covered applications and submissions, the statute requires information FDA may require to ensure the cyber device meets the provision. Its listed elements create four evidence routes:

1. A plan to monitor, identify and address postmarket cybersecurity vulnerabilities and exploits in a reasonable time, including coordinated vulnerability disclosure and related procedures.
2. Processes and procedures designed, developed and maintained to provide reasonable assurance that the device and related systems are cybersecure, plus the capability to make postmarket updates and patches available.
3. An SBOM covering commercial, open-source and off-the-shelf software components.
4. Other information FDA may require through regulation to demonstrate reasonable assurance that the device and related systems are cybersecure.

The second route also reaches beyond the sentence “we can issue updates.” The statutory text addresses a reasonably justified regular cycle for known unacceptable vulnerabilities and, as soon as possible out of cycle, critical vulnerabilities that could cause uncontrolled risks.

For commercial qualification, mark every route as available for the submitted version, available only for another version, under development, missing or not yet reviewed. That status is more useful than asking whether the manufacturer “has 524B.”

Question 3: What evidence sits outside that four-part statutory list?

A section 524B checklist is not the whole FDA cybersecurity review. FDA’s current guidance, Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, addresses secure product development and the documentation FDA recommends for devices with cybersecurity risk.

Depending on the product and risk, the evidence discussion can include cybersecurity risk management and threat modeling, security architecture, security requirements and implementation evidence, testing, unresolved anomalies, vulnerability-management planning, labeling and other device-specific material. These artifacts must support their claims. A network diagram is not automatically a security architecture analysis; a penetration-test report does not replace the threat model or postmarket process.

Keep these wider review artifacts in a separate section of the evidence index. That prevents the statutory SBOM from being treated as a universal cybersecurity certificate and prevents a complete-looking guidance checklist from obscuring a missing statutory element.

For a deeper distinction between component inventory and affected-status evidence, see when an SBOM and a VEX statement answer different questions. VEX means Vulnerability Exploitability eXchange, a statement about whether a specific product is affected by a known vulnerability.

Question 4: Do all records describe the submitted version?

Version mismatch is where a complete evidence list can still fail. The architecture may describe the current build while the SBOM came from a release candidate. The vulnerability plan may assign postmarket ownership for one product family while the application covers a new related system. Testing may predate a changed communications library.

Build one evidence-chain header before reviewing individual files:

• device name, model and hardware revision;
• software or firmware release and build identifier;
• related system and connectivity boundary;
• submission type and submission version;
• evidence artifact, revision, date and owner;
• change event that requires the artifact to be regenerated or reapproved.

When those identifiers agree, the consultancy can inspect substance. When they disagree, configuration and evidence control are the immediate problem. The establishment-level quality-system distinction is addressed separately in the FDA QMSR and ISO 13485 gap-assessment article; this page remains centred on one cyber device’s premarket evidence.

Question 5: Who can close each remaining gap?

The final evidence route must end with an accountable human, not “cybersecurity”. Regulatory affairs owns the submission index and FDA correspondence. Product security may own the threat model and vulnerability process. Engineering and release management may produce architecture, build and SBOM evidence. Quality may control procedures and approvals. Labeling specialists own the user-facing claims. The actual assignment varies, so the group message cannot supply it by implication.

A useful handoff says: which artifact is missing, which exact device/version it must cover, which claim it supports, who can release it and what submission decision is waiting. Keep unresolved cyber-device applicability, regulatory interpretation and submission acceptance with the sponsor’s qualified regulatory function.

TOP Prospect can connect related fragments from Telegram groups a user intentionally connects and is authorised to access, preserve original wording, source and time, remove duplicates and rank the discussion for human review. It cannot inspect a device, determine the statutory definition, enter a submission, validate an SBOM, contact participants or predict FDA action. If authorised-group discovery later becomes a procurement question, the pricing page lists the public product options.

Key facts

• Section 524B applies to specified premarket applications and submissions for a device that meets all parts of the cyber-device definition.
• The listed statutory evidence includes a postmarket vulnerability plan, secure processes and patch capability, an SBOM and other information FDA may require by regulation.
• FDA premarket cybersecurity guidance covers a broader evidence discussion than the statutory list alone.
• Every artifact must be tied to the submitted device and version; an artifact for another release does not close the chain.
• Neither the phrase “cyber device” nor a complete-looking cybersecurity package guarantees acceptance, clearance or approval.

FAQ

What is a cyber device under section 524B?

It is a device that includes sponsor-validated, installed or authorised software, can connect to the internet, and contains sponsor-validated, installed or authorised technological characteristics that could be vulnerable to cybersecurity threats. Assess all three parts for the submitted product.

What does section 524B require in a premarket submission?

It requires information FDA needs to ensure the cyber device meets the provision, including the postmarket vulnerability plan, secure processes and patch capability, an SBOM, and other information FDA may require by regulation.

Is an SBOM enough to satisfy section 524B?

No. It is one statutory element. The other statutory routes and the wider FDA premarket cybersecurity evidence still need to be addressed for the applicable device and risk.

Does the evidence package guarantee FDA clearance or approval?

No. FDA reviews the complete applicable submission. Cybersecurity evidence does not by itself determine acceptance, substantial equivalence, safety, effectiveness or the final regulatory decision.

Frequently asked questions

What is a cyber device under section 524B?

It is a device that includes sponsor-validated, installed or authorised software; can connect to the internet; and contains sponsor-validated, installed or authorised technological characteristics that could be vulnerable to cybersecurity threats. All parts of the definition must be assessed for the submitted device.

What does section 524B require in a premarket submission?

For a covered application or submission, the statute requires the information FDA needs to ensure the cyber device meets section 524B, including a postmarket vulnerability plan, processes providing reasonable assurance of cybersecurity and postmarket updates and patches, an SBOM, and other information FDA may require by regulation.

Is an SBOM enough to satisfy section 524B?

No. The SBOM is one statutory element. The submission must also address the vulnerability-management plan, secure processes and patch capability, while FDA guidance recommends additional evidence appropriate to the device and cybersecurity risk.

Does a section 524B evidence package guarantee FDA clearance or approval?

No. FDA reviews the applicable submission as a whole. A complete-looking cybersecurity package does not determine substantial equivalence, safety, effectiveness, acceptance or the final regulatory decision.

Sources and further reading

• 21 U.S.C. § 360n-2, Ensuring cybersecurity of devices, current preliminary edition accessed 12 August 2026↗
• FDA: Cybersecurity in Medical Devices—Quality Management System Considerations and Content of Premarket Submissions, accessed 12 August 2026↗
• FDA: Medical Device Cybersecurity, accessed 12 August 2026↗

RESEARCH & DEFINITIONS

How a Signal worth attention is found

See how Top Prospect finds and organizes Signals worth checking, keeps the original Telegram context, removes duplicates, and helps you decide what to review first. You decide whether to follow up and what to do next.

Open the methodology and core definitions →